New NIH Study Explores PEM Symptoms in ME/CFS
Yumu123 / Pixabay

New NIH Study Explores PEM Symptoms in ME/CFS

  For patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), post-exertional malaise (PEM) can be extremely debilitating and disruptive. PEM occurs when symptoms worsen or become more severe within 12-48 hours…

Continue Reading New NIH Study Explores PEM Symptoms in ME/CFS
BCX9930 Shows Promising Results for Patients with Previously Untreated PNH
source: pixabay.com

BCX9930 Shows Promising Results for Patients with Previously Untreated PNH

On September 30, 2020, BioCryst Pharmaceuticals ("BioCryst") announced promising data on their drug candidate BCX9930. The therapy, an orally administered Factor D inhibitor, is designed to treat patients with previously…

Continue Reading BCX9930 Shows Promising Results for Patients with Previously Untreated PNH
Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
source: pixabay.com

Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment

Historically, clinical trials have played an immense role in collecting patient data, understanding disease progression, and crafting more targeted treatments. This is especially true in the oncology realm. But according…

Continue Reading Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access
source: pixabay.com

Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access

According to a story from PR Newswire, Chiesi Global Rare Diseases and the biopharmaceutical company Protalix BioTherapeutics, Inc. have recently announced that they have launched an Expanded Access Program (EAP)…

Continue Reading Experimental Treatment for Fabry Disease to be Made Available Under Expanded Access
Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation
source: pixabay.com

Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Mereo BioPharma Group recently announced that its investigational therapy setrusumab has earned Rare Pediatric Disease designation from the US Food and…

Continue Reading Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation

The aHUS Foundation has Created a Medical Tracker for atypical Hemolytic Uremic Syndrome Patients

aHUS Tracking Atypical hemolytic uremic syndrome (aHUS) is a rare disease that causes blood clots to form within the small blood vessels in the kidneys. These clots lead to organ damage…

Continue Reading The aHUS Foundation has Created a Medical Tracker for atypical Hemolytic Uremic Syndrome Patients